dr. manish shah on met inhibitors not improving pfs in met-positive gec
Published 9 years ago • 146 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:18
dr. nghiem on challenges with immunotherapy in merkel cell carcinoma
-
1:19
dr. beckermann on tki/immunotherapy combinations in mrcc
-
1:18
dr. thigpen on comparing treatments in ovarian cancer
-
2:37
dr. spigel discusses the development of onartuzumab for the treatment of lung cancer
-
1:28
dr. usmani on current challenges in high-risk multiple myeloma
-
1:04:34
sk dharmalingam lecture series 29: shedding light on hepatocellular carcinoma
-
3:04
using imaging of steroid receptor and parp targets to improve endocrine therapy
-
1:27
dr. manns on risk factors for hepatitis c-related hepatocellular carcinoma
-
3:31
met fusions as a therapeutic target in nsclc
-
2:58
a case of mtc features and spindle cells
-
1:37
mono or combination immunotherapy for hnscc?
-
1:44
targeting mitochondrial vulnerabilities in multiple myeloma
-
1:39
section 3 does high risk disease impact proteasome inhibitor based therapy selection
-
3:07
understanding the heterogeneity of mantle cell lymphoma
-
24:02
solutions with/in/sight: katharine yen
-
4:38
emerging checkpoint inhibitors for hnscc
-
1:19:16
solutions with/in/sight: november 10th, 2011
-
0:54
kcrd induction for ndmm: myeloma xi trial analysis by molecular risk